133 related articles for article (PubMed ID: 29139250)
1. [Clinical safety imtensive hospital monitoring on Shenfu injection with 30 106 cases].
Wang ZF; Yu JY; Xie YM
Zhongguo Zhong Yao Za Zhi; 2017 Aug; 42(15):2871-2876. PubMed ID: 29139250
[TBL] [Abstract][Full Text] [Related]
2. [Post-marketing clinical safety assessment of Shenmai injection based on active monitoring and passive monitoring in large data background].
Wang LX; Xie YM; Ai QH; Song NB
Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4752-6. PubMed ID: 27245017
[TBL] [Abstract][Full Text] [Related]
3. [Post-marketing safety surveillance of Diemailing Kudiezi injection: real world study in 30 233 cases].
Liao X; Yu DD; Xie YM; Zhang YL; He Y; Zhang Y; Liu Y; Yi DH; Wang YY
Zhongguo Zhong Yao Za Zhi; 2017 Aug; 42(15):2857-2863. PubMed ID: 29139248
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of influencing factors on adverse reaction of Shengfu injection based on prospective active safety monitoring].
Wang ZF; Zhao W; Zhang Y; Xie YM
Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4746-51. PubMed ID: 27245016
[TBL] [Abstract][Full Text] [Related]
5. [Study on 10 409 cases of post-marketing safety Danhong injection centralized monitoring of hospital].
Li X; Tang J; Meng F; Li C; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2783-5. PubMed ID: 22292364
[TBL] [Abstract][Full Text] [Related]
6. [Intensive hospital monitoring of Shuxuening injection in 30 209 cases].
Jiang JJ; Xie YM; Zhang Y; Li MQ; Zhao YB; Wen ZH; Li XL; Yi DH; Zhang YK
Zhongguo Zhong Yao Za Zhi; 2017 Aug; 42(15):2883-2888. PubMed ID: 29139252
[TBL] [Abstract][Full Text] [Related]
7. [Post-marketing surveillance of
Li XX; Zhuo L; Yang YH; Zhan SY; Zhai SD
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Feb; 38(2):248-252. PubMed ID: 28231676
[No Abstract] [Full Text] [Related]
8. [A postmarketing surveillance study on 31,724 patients using Dengzhan Xixin injection in hospital].
Li YY; Lei L; Xie YM
Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4757-61. PubMed ID: 27245018
[TBL] [Abstract][Full Text] [Related]
9. [Clinical safety studies based on 30 026 post-marketing cases of Shenqi Fuzheng injection by intensive hospital monitoring nested NCCS].
Wang LX; Xie YM; Ai QH; Xu WF
Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4739-45. PubMed ID: 27245015
[TBL] [Abstract][Full Text] [Related]
10. Clinical assessment of Shenfu injection loading in the treatment of patients with exacerbation of chronic heart failure due to coronary heart disease: study protocol for a randomized controlled trial.
Liu C; Hou Y; Wang X; Zhao Z; Liu Z; Zhai J; Mao J; Shang H
Trials; 2015 May; 16():222. PubMed ID: 25994188
[TBL] [Abstract][Full Text] [Related]
11. Post-marketing safety surveillance and re-evaluation of Xueshuantong injection.
Li C; Xu T; Zhou P; Zhang J; Guan G; Zhang H; Ling X; Li W; Meng F; Liu G; Lv L; Yuan J; Li X; Zhu M
BMC Complement Altern Med; 2018 Oct; 18(1):277. PubMed ID: 30326892
[TBL] [Abstract][Full Text] [Related]
12. Postmarketing studies on safety of Dengfeng shenmai injection.
Wang L; Zhang W; Xie Y; Bai Y; Wang M; Ai Q
J Tradit Chin Med; 2013 Dec; 33(6):827-31. PubMed ID: 24660618
[TBL] [Abstract][Full Text] [Related]
13. [Apply association rules to analysis adverse drug reactions of shuxuening injection based on spontaneous reporting system data].
Yang W; Xie YM; Xiang YY
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3616-20. PubMed ID: 25532406
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of clinical use of post-marketing hospital centralized monitoring of Xiyanping injection].
Zhao Y; Shi C; Huang P
Zhongguo Zhong Yao Za Zhi; 2016 Feb; 41(4):743-747. PubMed ID: 28871704
[TBL] [Abstract][Full Text] [Related]
15. [Differential analysis of different study types in clinical safety evaluation of Xuebijing Injection].
Li Q; Jin XY; Zhou X; Pang WT; Wang KY; Li N; Zheng WK
Zhongguo Zhong Yao Za Zhi; 2021 Feb; 46(3):712-721. PubMed ID: 33645039
[TBL] [Abstract][Full Text] [Related]
16. Postmarketing evaluation on the safety and effectiveness of deng-zhanxixin injection made from Dengzhanxixin (Herba Erigerontis Breviscapi).
Li Y; Lin G; Xie Y; Zhang W; Guo T
J Tradit Chin Med; 2015 Feb; 35(1):99-103. PubMed ID: 25842735
[TBL] [Abstract][Full Text] [Related]
17. Safety of the Xuesaitong injection in China: results from a large-scale multicentre post-marketing surveillance study in a real-world setting.
He Y; Gao XM; Li L; Liu XG; Liu W; Hong XJ; Huang BH; Yang HL; Xue MH; Wu XJ; Liu JF
Curr Med Res Opin; 2020 Dec; 36(12):1947-1953. PubMed ID: 33016133
[TBL] [Abstract][Full Text] [Related]
18. [Research and practice about risk control of shenfu injection].
Wang ZF; Tian DL; Zhang W; Xie YM
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3641-4. PubMed ID: 25532412
[TBL] [Abstract][Full Text] [Related]
19. Post-marketing safety monitoring of shenqifuzheng injection: a solution made of dangshen (Radix Codonopsis) and huangqi (Radix Astragali Mongolici).
Ai Q; Zhang W; Xie Y; Huang W; Liang H; Cao H
J Tradit Chin Med; 2014 Aug; 34(4):498-503. PubMed ID: 25185371
[TBL] [Abstract][Full Text] [Related]
20. Establishment of safety evidence for Xingxue Shuxuening injection.
Yang W; Zhang W; Xie Y; Han B
J Tradit Chin Med; 2014 Oct; 34(5):604-8. PubMed ID: 25417413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
